整理 | GLP1减重宝典内容团队 近年，GLP-1受体激动剂如司美格鲁肽和替尔泊肽因显著的减重与控糖效果受到关注。随着替尔泊肽获批用于治疗阻塞性睡眠呼吸暂停 （OSA），其应用范围已延伸到代谢疾病之外。专家认为，这一进展正推动睡眠医学进入新阶段。"睡眠呼吸暂停正进入一个药物也能 介入的时代，而不仅是依赖CPAP等设备，" 研究者认为替尔泊肽在OSA上的应用只是开端。"这类药物可能重新定义睡眠呼吸暂停及相关疾病的治疗方式。"然而目前仍需合理管理 患者预期，并推动其纳入综合治疗框架。"肥胖是一种慢性疾病，需要长期管理。GLP-1类药物具有变革性，但最好与营养、运动和行 为干预配合使用。关键在于改善长期健康，而不是只追求快速减重。" 加州大学圣迭戈分校的睡眠研究者Atul Malhotra表示，GLP-1类药物的作用不仅限于减重，可能还涉及代谢、炎症甚至神经调节机制。 肥胖是OSA最重要的可控风险因素之一，减重常带来明显改善。NYU Langone睡眠中心的Alcibiades Rodriguez表示："我们经常看到患 者通过传统方式、代谢手术或GLP-1类药物减重后，睡眠呼吸暂停得到改善，甚至完全缓解。"早期， ...

整理 | GLP1减重宝典内容团队 加州大学圣迭戈分校的睡眠研究者Atul Malhotra表示，GLP-1类药物的作用不仅限于减重，可能还涉及代谢、炎症甚至神经调节机制。 肥胖是OSA最重要的可控风险因素之一，减重常带来明显改善。NYU Langone睡眠中心的Alcibiades Rodriguez表示："我们经常看到患 者通过传统方式、代谢手术或GLP-1类药物减重后，睡眠呼吸暂停得到改善，甚至完全缓解。"早期，他主要在为糖尿病或减重开具 GLP-1药物的患者中观察到这些改善，如今该药已获批用于OSA，他也将其纳入常规治疗。"一些患者减重后从每晚依赖CPAP，变成几 乎不再需要使用。"研究也在揭示这些药物对睡眠的积极影响可能超越体重因素，为管理代谢、心肺和睡眠健康提供更多思路。 点击关注，追踪最新GLP-1资讯 替尔泊肽获批用于OSA是一个里程碑。这是首个被允许用于睡眠呼吸暂停的GLP-1药物，也是首个专门用于OSA治疗的FDA批准药物。 此前，OSA主要依靠CPAP等机械手段或外科干预。该批准基于SURMOUNT-OSA研究，结果显示在肥胖人群中，替尔泊肽可显著降低 AHI评分，并推动部分患者从重度转 ...

Core Insights - The article discusses the health risks associated with Obstructive Sleep Apnea (OSA), emphasizing its impact on various bodily systems and the importance of timely diagnosis and treatment [1][2]. Group 1: Health Risks of OSA - OSA can lead to complete airway collapse during sleep, causing repeated breathing interruptions and a cycle of hypoxia and awakening, which can result in multi-system damage [1]. - The cardiovascular system is particularly affected, with each apnea episode causing significant stress, leading to the release of stress hormones, vascular constriction, and increased blood pressure, which raises the risk of hypertension, coronary heart disease, and stroke [1]. - The kidneys may also suffer from repeated hypoxia, leading to a gradual decline in function due to activated abnormal endocrine pathways [2]. Group 2: Metabolic and Neurological Implications - OSA is linked to insulin resistance, type 2 diabetes, and dyslipidemia, creating a challenging "iron triangle" of metabolic disorders [2]. - Nighttime hypoxia disrupts normal glucose and lipid metabolism, making it difficult to control blood sugar and lipids, which in turn exacerbates OSA [2]. - OSA can lead to brain damage, particularly affecting the hippocampus, resulting in memory loss, attention deficits, and slower reaction times due to its sensitivity to hypoxia [2]. Group 3: High-Risk Populations and Treatment - High-risk groups for OSA include males, overweight individuals, and those with hypertension or diabetes, who may experience symptoms like persistent snoring, nighttime awakenings, and daytime sleepiness [2]. - Diagnosis can be made through sleep monitoring in hospitals or at home, with treatment options varying from oral appliances for mild to moderate cases to non-invasive ventilators or surgical options for more severe cases [2]. - Treatment should be complemented by lifestyle changes, including weight control, smoking cessation, and maintaining a regular sleep schedule, as snoring is a health warning rather than a sign of restful sleep [2].

Core Insights - Cardiovascular diseases are increasingly affecting younger populations, with stress and anxiety identified as significant risk factors for heart health [1][5] - Obstructive Sleep Apnea (OSA) is a rising concern, with an estimated 1.76 billion people in China affected, making it a critical health issue [1][2] - The diagnosis rate of OSA is alarmingly low, with less than 1% in China and only 20% in the U.S., highlighting the need for increased awareness and screening [4] Group 1: Cardiovascular Health - Cardiovascular diseases are the leading cause of death, with a notable increase in cases among younger individuals [1] - Emotional factors, particularly stress and anxiety, are significant contributors to cardiovascular risks in young people [5] - The theme for World Heart Day 2023 is "Rhythm Never Stops," emphasizing the importance of continuous heart health awareness [1] Group 2: Obstructive Sleep Apnea (OSA) - OSA is often misperceived as mere snoring, but it can lead to serious complications such as hypertension, with over 47% of OSA patients in China suffering from high blood pressure [2][4] - The prevalence of OSA is expected to rise, with projections indicating that the number of affected individuals in China could exceed 200 million this year [1] - Diagnosis of OSA typically involves sleep monitoring, which can be conducted in hospitals or at home using portable devices [4]

Core Insights - The approval of tirzepatide (brand name: Mounjaro) by the NMPA for treating moderate to severe obstructive sleep apnea (OSA) in adults marks a significant milestone as it is the first and only prescription drug for OSA globally [1] - Clinical data from Eli Lilly indicates that adult patients receiving tirzepatide treatment experience an average weight loss of 20% and a reduction of at least 27 episodes of hypopnea or apnea per hour during sleep [1] - The prevalence of OSA in China is estimated at 23.6%, with 8.8% being moderate to severe cases, and approximately 41% of these patients are also obese [2] Company Developments - Eli Lilly has received approval for tirzepatide for two indications in the past year: type 2 diabetes and long-term weight management, with the latest approval for OSA requiring dietary control and increased physical activity [1] - The FDA approved the OSA indication for tirzepatide in December last year, and further approvals in more countries will enhance Eli Lilly's competitive position in the weight loss drug market [3] Industry Context - OSA is characterized by airway obstruction during sleep, leading to breathing interruptions, and is associated with various cardiovascular diseases [2] - The number of individuals suffering from OSA in China is projected to exceed 200 million this year, indicating a growing public health concern [2]